Healthcare Global Enterprises Ltd

The board of Healthcare Global Enterprises at its meeting held on 24 February 2025 has approved the terms of rights issue: Instrument: Fully paid-up equity shares of face value of Rs 10 each. Total number of Rights Equity Shares and Rights Issue size: 82,94,566 Rights Equity Shares each for an amount aggregating to Rs 424.68 crore (assuming full subscription and payment of call monies). Rights Issue Price: Rs 512 (Rupees Five Hundred and Twelve only) per Rights Equity Share (including a premium of Rs 502 (Rupees Five Hundred and Two only) per Rights Equity Share) Concept of Rights Entitlement: The shareholders holding equity shares of the Company as on the Record date ('eligible equity shareholders') will be entitled to Rights Entitlement ('REs'). REs shall be credited prior to the issue opening date, in the respective demat account of the eligible equity shareholders ('RE Holders') under the ISIN: INE075I20017. The Company has made necessary arrangements with NSDL and CDSL for credit of REs in the respective demat account of the eligible equity shareholders. RE holders can apply for Rights Issue or renounce the REs in full or in part. Record date: 02 March 2026 Issue opening date: 11 March 2026 Issue closing date: 25 March 2026 Date of listing of rights issue: 01 April 2026 Rights Entitlement Ratio: The Rights Equity Shares are being offered on a rights basis to Eligible Equity Shareholders in the ratio of 1 (One) Rights Equity Shares for every 17 (Seventeen) fully paid-up Equity Shares held on the Record Date. Powered by Capital Market - Live

Healthcare Global Enterprises will hold a meeting of the Board of Directors of the Company on 24 February 2026.Powered by Capital Market - Live

These funds will be raised by offering new shares to the company's existing eligible equity shareholders. The total number of securities to be issued will be finalized by the board's rights issue committee at a later stage. The company further said that the record date, which determines shareholder eligibility, will be decided and notified in a subsequent filing. HealthCare Global Enterprises is one of India's largest oncology hospital chains. HCG operates 25 medical care centers across 19 cities with best-in-class infrastructure including 2,500 beds, nearly 100 operating theaters and 40 linear accelerator machines (LINACs). HealthCare Global Enterprises (HCG) is India's largest dedicated cancer hospital network, operating 25 hospitals across India and Africa. HCG's comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof. Under 'Milann', HCG operates fertility centers as well. The company had reported a net loss of Rs 9.43 crore in the quarter ended December 2025 as against net profit of Rs 6.98 crore during the previous quarter ended December 2024. Sales rose 13.21% to Rs 631.18 crore in Q3 FY26 over Q3 FY25. The scrip was down 0.08% to currently trade at Rs 578 on the BSE. Powered by Capital Market - Live

Healthcare Global Enterprises will hold a meeting of the Board of Directors of the Company on 17 February 2026.Powered by Capital Market - Live

Net loss of Healthcare Global Enterprises reported to Rs 9.43 crore in the quarter ended December 2025 as against net profit of Rs 6.98 crore during the previous quarter ended December 2024. Sales rose 13.21% to Rs 631.18 crore in the quarter ended December 2025 as against Rs 557.55 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales631.18557.55 13 OPM %17.3615.85 - PBDT67.2553.22 26 PBT6.60-3.30 LP NP-9.436.98 PL Powered by Capital Market - Live

Healthcare Global Enterprises will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live

HealthCare Global Enterprises has appointed Manish Mattoo, Executive Director and Chief Executive Officer, as the interim Chief Financial Officer and Key Managerial Personnel of the Company. The appointment shall be effective from 01 December 2025, and shall remain in force until a new Chief Financial Officer is appointed by the Board of Directors and assumes office as the Chief Financial Officer.Powered by Capital Market - Live

Net profit of Healthcare Global Enterprises declined 9.56% to Rs 16.27 crore in the quarter ended September 2025 as against Rs 17.99 crore during the previous quarter ended September 2024. Sales rose 16.78% to Rs 645.16 crore in the quarter ended September 2025 as against Rs 552.47 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales645.16552.47 17 OPM %19.1118.51 - PBDT82.6277.39 7 PBT19.8227.65 -28 NP16.2717.99 -10 Powered by Capital Market - Live

Net profit of Healthcare Global Enterprises declined 39.94% to Rs 10.78 crore in the quarter ended September 2025 as against Rs 17.95 crore during the previous quarter ended September 2024. Sales rose 4.86% to Rs 344.41 crore in the quarter ended September 2025 as against Rs 328.45 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales344.41328.45 5 OPM %18.0918.75 - PBDT44.7650.79 -12 PBT14.6022.91 -36 NP10.7817.95 -40 Powered by Capital Market - Live

Healthcare Global Enterprises will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live